Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT

Inclusion Criteria: * Children 1 - 3 years old at inclusion * Positive baseline challenge at a maximum of the 250 mg peanut protein-dose with at least one objective symptom, or positive peanut challenge performed in the clinic in a similar way within 1 year from study start. * IgE-ab to peanut and/or Ara h 2 ≥0.1 kUA/l, analyzed within 12 months from start of study * Written consent for participation in the study from both Guardians Exclusion Criteria: * Other serious illness * Previously life-threatening anaphylaxis (intensive care), regardless of the triggering agent * A history of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, severe chronic gastroesophageal reflux disease (GERD), symptoms of dysphagia, unclear recurrent GI disorders * Participation in another intervention study, if included in intervention Group * Severe uncontrolled asthma * Ongoing medication with biological drugs or oral steroids